Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance

BACKGROUND: On the basis of phase III CheckMate 141 results, nivolumab was approved for recurrent or metastatic head and neck cancer after undergoing platinum-containing chemotherapy in Japan. This post-marketing surveillance aimed to evaluate the safety and effectiveness of nivolumab for head and n...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahara, Makoto, Kiyota, Naomi, Nibu, Ken-ichi, Akamatsu, Ayumi, Hoshino, Tomohiro, Hayashi, Ryuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364900/
https://www.ncbi.nlm.nih.gov/pubmed/34110532
http://dx.doi.org/10.1007/s10147-021-01949-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364900/
https://www.ncbi.nlm.nih.gov/pubmed/34110532
http://dx.doi.org/10.1007/s10147-021-01949-1

Ejemplares similares